Siemens Healthcare has received FDA 501(k) marketing clearance for a software package that helps in the assessment of cerebral blood flow during interventional procedures.
Siemens Healthcare has received FDA 501(k) marketing clearance for a software package that helps in the assessment of cerebral blood flow during interventional procedures.
The syngo Neuro PBV IR (Parenchymal Blood Volume Interventional Radiology) is intended to provide visual assistance in diagnosis and treatment of vessel malformations, such as aneurysms, arteriovenous malformations, and stenosis, the company said. The software displays a color-coded map of cerebral tissue in the angiography suite, which can help in the treatment of stroke patients.
Syngo Neuro PBV uses cone-beam computed tomography (CT) to produce a qualitative colorized image similar to CT perfusion, the company said. It is designed for the visualization of contrast-enhanced blood distribution in the arterial and venous vessels in the head using color-coded relative values for diagnosis.
Parenchymal blood volume information is acquired with two C-arm rotations around the patient and a steady-state contrast injection. The system then applies processing algorithms to generate a neurological PBV map, according to the company.
“Neurovascular imaging has evolved from simple anatomical 2D rendition of blood vessels to 3D spatial visualization and, with the Neuro PBV, to physiological functional imaging of the brain,” Michel E. Mawad, MD, Baylor College of Medicine, Houston, said in the company’s press release. “Neuro PBV is a promising technique that will add valuable information about the viability of the brain and should help guide the interventionalist in the decision-making process of revascularization procedures."
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.